



*News Release*

**FOR IMMEDIATE RELEASE**

Contact: Beth Claseman, NeoChord Inc. (952) 698-7807; [bclaseman@neochord.com](mailto:bclaseman@neochord.com)

## **NeoChord Crosses 100<sup>th</sup> Patient Milestone; Appoints Michael Dale to Board of Directors**

EDEN PRAIRIE, MN, April 4, 2014—NeoChord Inc., a developer of minimally invasive devices and procedures for mitral valve repair, today announced the treatment of its 100<sup>th</sup> patient. “This is an important achievement for our Company, and it coincides with a continuing upsurge in the number of patients scheduled across Europe for the procedure” said Giovanni Speziali, MD, NeoChord’s Chief Medical Officer. He also commented, “We are pleased with our acute procedure success rate which is >96% in patients with favorable anatomy, and we look forward to presenting our mid and long term results from the Registry in upcoming international meetings”.

In separate news NeoChord recently added Mr. Michael Dale to its board of directors. John Seaberg, CEO said, “We are fortunate to have Mike on our board. He has deep worldwide experience in structural heart disease markets. His previous role as CEO of publicly traded ATS Medical (acquired by Medtronic in August 2010) gave him valuable perspective on managing growth in our space.”

### **About NeoChord, Inc.**

Based in Eden Prairie, Minn., NeoChord, Inc. is a privately held medical technology company focused on advancing the treatment of mitral regurgitation. The Company received CE marking in Dec. 2012 for the DS1000 device for minimally invasive mitral valve repair via surgical implantation of artificial chordae tendinae. Mitral regurgitation is a progressive disease that can result in atrial fibrillation, congestive heart failure, and death when left untreated. For more information, visit: [www.NeoChord.com](http://www.NeoChord.com).

*The NeoChord DS1000 System is CE marked and approved for sale in Europe.  
CAUTION: In the United States, the NeoChord device is not available for commercial use.*

#####

700224-001 Rev 1